Advances in Biology and Therapy of Multiple Myeloma PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Advances in Biology and Therapy of Multiple Myeloma PDF full book. Access full book title Advances in Biology and Therapy of Multiple Myeloma by Nikhil C. Munshi. Download full books in PDF and EPUB format.
Author: Nikhil C. Munshi
Publisher: Springer Science & Business Media
ISBN: 146144666X
Category : Medical
Languages : en
Pages : 322
Get Book
Book Description
Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.
Author: Nikhil C. Munshi
Publisher: Springer Science & Business Media
ISBN: 1461452600
Category : Medical
Languages : en
Pages : 291
Get Book
Book Description
Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.
Author: Nikhil C. Munshi
Publisher: Springer Science & Business Media
ISBN: 146144666X
Category : Medical
Languages : en
Pages : 322
Get Book
Book Description
Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.
Author: James R. Berenson
Publisher: Springer Science & Business Media
ISBN: 159259817X
Category : Medical
Languages : en
Pages : 523
Get Book
Book Description
Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.
Author: P. Leif Bergsagel
Publisher:
ISBN: 9781588291387
Category : Multiple myeloma
Languages : en
Pages : 400
Get Book
Book Description
discusses the advances in molecular and cellular biology that have affected all fields of biology and have had a tremendous impact on the understanding of the biology of myeloma;reviews the dramatic clinical response to novel agents that has prompted a re-evaluation of important signaling pathways in myeloma;covers bone marrow microenvionments, molecular genetics, and other various genetic changes.
Author: Sagar Lonial
Publisher: Springer Science & Business Media
ISBN: 1597455644
Category : Medical
Languages : en
Pages : 674
Get Book
Book Description
Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.
Author: Morie A. Gertz
Publisher: Springer Science & Business Media
ISBN: 1461485207
Category : Medical
Languages : en
Pages : 313
Get Book
Book Description
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
Author: Michael Potter
Publisher: Elsevier
ISBN: 1483161536
Category : Health & Fitness
Languages : en
Pages : 302
Get Book
Book Description
Progress in Myeloma: Biology of Myeloma is a collection of research studies dealing with the clinical and experimental plasma cell tumors. This work is composed of 14 chapters that provide a particularly advantageous basis for defining in biochemical and genetic terms the nature of critical alterations in the neoplastic transformation of immunoglobulin producing cells. The introductory chapters survey the epidemiology of multiple myeloma and related plasma cell disorders, as well as the mechanism of in vitro bone resorption by human myeloma cells. The subsequent chapters describe the clinical manifestations of the Waldenström's macroglobulinemia in black and white South Africans; myeloma models to evaluate the activation and suppression of normal lymphocytes; and the cellular and molecular mechanisms of murine myeloma cell growth and differentiation regulation. These topics are followed by discussions of the characteristics of multiple myeloma as an immunodeficiency disease, the myeloma growth kinetics, and the extent of clonal involvement in multiple myeloma. A chapter explores the use of anti-idiotypic antibodies in the regulation of the myeloma tumor cell growth and non-neoplastic B cell clones. The concluding chapters look into the chromosomal changes, therapeutic trials, and genetic basis of myeloma. This book will prove useful to oncologists, cell biologists, immunologists, and researchers.
Author: Khalid Ahmed Al-Anazi
Publisher:
ISBN: 178985217X
Category : Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Languages : en
Pages : 236
Get Book
Book Description
This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries.
Author: J. S. Malpas
Publisher: Elsevier Health Sciences
ISBN:
Category : Medical
Languages : en
Pages : 472
Get Book
Book Description
This book was prompted by a renewed interest in the biology of myeloma, new concepts with regard to its clinical evolution, and options for therapy that have not been available before. Myeloma has always involved many systems and caused many problems for the clinician. It has become a focus of attention for the scientist and clinician.
Author: S. Vincent Rajkumar
Publisher: Cambridge University Press
ISBN: 1139473492
Category : Medical
Languages : en
Pages : 207
Get Book
Book Description
Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists caring for myeloma patients. The book covers all myeloma subtypes and related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome.
